Strand is excited to participate in the 44th Annual J.P. Morgan Healthcare Conference, January 12-15, in San Francisco. Our CEO, Dr. Ramesh Hariharan, along with the team, Radhakrishna Bettadapura, Jaya Singh, PhD and Ernie Hobbs, will be at the event. Feel free to reach out to schedule a meeting. We look forward to connecting with you! hashtag#JPM26 hashtag#JPM2026

RIL Plans Foray Into Genomic Diagnostics #Genomics I #Diagnostics I #Public_health I #Preventive_care I @StrandLife I @reliancegroup Read more: health.economictimes.indiati…

#India Mukesh Ambani to shake up #healthcare #diagnostics as Reliance plans to offer #genomictesting under ₹1,000, down from current rates of ₹10,000, leveraging @StrandLife buff.ly/WqhTqw8

We had a great time presenting at Seqera Sessions in Durham last week! It was a privilege to share how Strand Life Sciences is using Nextflow and the Seqera Platform to drive massive efficiency gains for our clients. If you are interested in how we achieved a 35x increase in throughput and a 66% reduction in costs, check out the full case study below. Thanks to the Seqera team for hosting such a fantastic event! hashtag#Nextflow hashtag#Seqera hashtag#Bioinformatics hashtag#Genomics hashtag#PipelineDevelopment hashtag#LifeSciences hashtag#CloudComputing

After a fantastic morning of @nextflowio training, the team are ready for an afternoon of #Seqera Sessions here in Durham, North Carolina! 🇺🇸 Get ready for an afternoon of live demos and expert talks, including from @StrandLife

⌛ Last chance! Seqera Sessions Durham is happening tomorrow! 🇺🇸 Join us in the heart of North Carolina’s Research Triangle for a day of @nextflowio training, expert talks, and networking with the local bioinformatics community! 🎟️ Register now: hubs.la/Q03SNwPk0

New Case Study with @StrandLife 🎉 Strand faced growing demands across pharma, diagnostics, and precision medicine clients. The bottleneck: their existing workflow management system. To address this, they undertook a strategic initiative to standardize their bioinformatics operations. By migrating legacy pipelines to @nextflowio and deploying on Seqera, Strand: ☑️ Reduced workflow execution time by up to 55% ☑️ Scaled sample throughput by 35x ☑️ Achieved ~66% reduction in total costs 📚 Read now: hubs.la/Q03Ptc-J0

Excited to see @Alnylam join the Alliance for Genomic Discovery, expanding diverse clinical genomic data to fuel precision medicine breakthroughs! As @illumina's partner for nearly a decade and official ICA Implementation Partner, we're proud to support platforms like ICA that power these innovations. Here's to more discoveries ahead! 🚀 #Genomics #PrecisionMedicine

In Q3, we brought our mission to life across multiomics, oncology, and data-driven discovery — strengthening our leadership in precision medicine. 1️⃣ Accelerating proteomics at scale We launched Illumina Protein Prep, expanding next-generation proteomics to researchers worldwide. Measuring 9,500 unique human protein targets, it’s helping uncover new biomarkers across cancer, cardiometabolic, and immune diseases. Early data from a study by Genomics England [tag] showed a 7.5% boost in diagnostic yield for rare disease, underscoring the power of multiomics to transform research insights into impact. 2️⃣ Advancing genomic discovery Alnylam Pharmaceuticals [tag] joined the Alliance for Genomic Discovery (AGD), expanding one of the world’s most diverse clinical genomic datasets. Leveraging DRAGEN™ and Illumina Connected Analytics, the alliance is accelerating therapeutic discovery across populations and disease areas. 3️⃣ Expanding access to precision oncology New pharma collaborations will develop KRAS-focused companion diagnostics on TruSight™ Oncology Comprehensive — a key step toward globally distributable, tumor-agnostic testing that connects more patients to targeted therapies. 4️⃣ Leading with purpose For the second consecutive year, Illumina was named to [tag]TIME’s World’s Most Sustainable Companies list and U.S. News & World Report’s Best Companies to Work For. From 100% renewable electricity to an 80% reduction in packaging, our commitment to sustainability and people remains central to how we innovate. Together, these achievements highlight our commitment to science, clinical translation, and sustainability — all in service of our mission to unlock the power of the genome to improve human health. Learn more at illumina.com

HUGE NEWS! The FDA has approved UCB’s Kygevvi (doxecitine and doxribtimine) to treat the mitochondrial disease thymidine kinase 2 deficiency (TK2d). You can find the full prescribing details and announcement here: bit.ly/4hH4Yhr

Great to see our work with the Seqera Platform featured in a new case study, now live on the @Seqera website. We're focused on helping life sciences organizations solve their biggest data challenges. This story highlights how we partner with clients to deliver the expert Nextflow implementation services they need to accelerate their science. Read the details here: seqera.io/case-studies/stran… #Bioinformatics #Nextflow #Genomics #Implementation #LifeSciences

Amid uncertainty, one trend is unmistakable: 85% of top pharma companies are investing more in #AI, making it an immediate priority—even as budgets tighten. The new @BioSpace report (link below) is a fascinating pulse-check: “Business as usual” is no longer a winning strategy when speed to market and operational efficiency define who leads and who follows. From what we see at Strand, this sector-wide urgency matches real-world conversations. Most forward-thinking teams aren’t just experimenting at the edges—they’re integrating AI into core workflows, sometimes with help from partners who build, automate, and guide alongside internal teams. The best results often come from blending internal scientific expertise with flexible outside support to optimize pipelines, close skill gaps, and deliver value now, not in next year’s planning cycle. For organizations wrestling with bandwidth, skills gaps, or the question of “buy vs. build,” a collaborative approach is fast becoming the industry standard. In our work, we’ve seen that transparent partnerships, iterative delivery, and a focus on solving genuine bottlenecks—not chasing hype—pay lasting dividends. AI is no longer a niche project in this field. It’s the backbone of what’s next. 🔗 Read the full article: biospace.com/job-trends/amid… #LifeSciences #Pharma #DigitalTransformation #AIInPharma #Consulting #Strand

As we gear up for our fun-filled event this week, we're excited to announce we have 2 more talks lined up. So make sure to register today for an evening of engaging talks, great food, and networking! 📅 September 10, 2025 📍 Myriad Genetics' SSF facility in the Grand Nexus Building, 233 E Grand Ave. South San Francisco, CA ⏰ 5 - 9PM PST Hosted by Shane Brubaker, this program features experts from Myriad Genetics, Strand Life Sciences, Roke Biotechnologies, and Castle Biosciences, Inc., presenting real-world applications in bioinformatics. 🎤 Featured Talks: ▫️ Talk 1 (Roke Biotechnologies): Unlocking Advanced Protein Manufacturing Using Systems Engineering Presenter: Romel Menacho Melgar, CEO of Roke Biotechnologies ▫️ Talk 2 (Strand Life Sciences): Automated Metadata Ingestion and Harmonization in Strand's scRNA-seq Portal and Beyond Presenter: Badri Padhukasahasram, VP of Data Science, Strand Life Sciences ▫️ Talk 3 (Strand Life Sciences & Myriad Genetics): Master Infrastructure Set Up for Multiple Pipeline Integrations in Minimal Residual Disease (MRD) Presenters: Moulika Kirthi, Software Engineer, Strand Life Sciences Radhakrishna Bettadapura, VP, Research Informatics, Strand Life Sciences Erik Anderson, Staff Software Engineer, Myriad Genetics Benjamin Vaisvil, Staff Software Engineer, Myriad Genetics ▫️ Talk 4 (Castle Biosciences, Inc. Biosciences Inc.): Genetic Algorithms For High Dimensional Feature Refinement Presenter: Kyle Covington, Director of Bioinformatics, Castle Biosciences Inc The event will be recorded. For a copy, contact Jaya Singh, PhD (jaya@strandls.com) or Shane Brubaker (shanebrubaker55@gmail.com). 👉 Register here: docs.google.com/forms/d/e/1F… Parking will be available in the Nexus garage (next to Myriad) until 9:30PM. hashtag#BayAreaBioinformatics hashtag#GenomicsData hashtag#GenomicsWorkflows hashtag#NGSWorkflows hashtag#ComputationalGenomics hashtag#BioinformaticsTools hashtag#BioinformaticsSolutions hashtag#BioinformaticsInfrastructure hashtag#PipelineAutomation

Big news from OpenAI and Oracle on the Stargate project! They're expanding with an additional 4.5 gigawatts of data center capacity in the U.S., pushing the total to over 5 gigawatts, with parts of the Stargate I site in Abilene, Texas, already operational. This is a massive step for AI infrastructure, and it’s got me thinking about what it means for genomics analysis and drug discovery. At Strand Life Sciences, we’re all about tackling complex bioinformatics challenges, from building NGS pipelines to curating multi-omics data for pharma and diagnostics companies. The Stargate project’s scale—potentially powering over 2 million Nvidia chips—could be a game-changer for our field. With this kind of compute power, we could see faster processing of large-scale genomic datasets, like whole-exome sequencing or single-cell RNA-seq. It could accelerate variant interpretation, cutting rare disease diagnosis times significantly. For drug discovery, this infrastructure could enable more robust AI-driven biomarker studies or protein interaction analyses. But here’s the flip side—will this massive compute boost be accessible enough for smaller players in genomics and drug discovery, or will it mostly benefit the big dogs? And with the industry already navigating funding uncertainties, as we’ve seen with recent NIH cuts, how will this shape R&D priorities? I’d love to hear your thoughts. How do you see this kind of AI infrastructure impacting genomics and drug discovery? If you’re grappling with data challenges or looking to leverage AI for your pipelines, let’s connect—I’m happy to chat about how Strand can help. cnb.cx/4m8tdGC

#BTMagazine | Ramesh Hariharan, CEO of @StrandLife, shares how owning up to failure—rather than shifting blame—helped the Bengaluru-based in silico tech firm bounce back from a funding crisis and emerge stronger. businesstoday.in/magazine/be…

thesciencecircuit.blogspot.c… The Science Circuit Friday, 20 December 2024 Unlocking Insights: Simplifying Single-Cell Data with Strand’s scRNA Portal Simplifying single-cell data exploration with Strand’s scRNA portal In the rapidly advancing world of single-cell RNA sequencing (scRNA-seq), navigating complex datasets can be a major challenge. Strand’s scRNA Portal is designed to transform this challenge into an opportunity by harmonizing publicly available datasets, making disease-specific omics data accessible, actionable, and ready for discovery.

Media Release - Strand Life Sciences, a Reliance subsidiary, Launches Pioneering Blood-based Test for Early Detection of Multiple Cancers CancerSpot works off a simple blood sample and uses a proprietary genome sequencing and analysis process to identify DNA methylation signatures of cancer Bengaluru, 2nd December 2024: Leading genomics and bioinformatics company Strand Life Sciences, a subsidiary of Reliance Industries Limited, has launched a novel blood-based test for early detection of multiple cancers. Called CancerSpot, the test uses the latest globally accepted methylation profiling technology to identify cancer tumor DNA fragments. CancerSpot works off a simple blood sample and uses a proprietary genome sequencing and analysis process to identify DNA methylation signatures of cancer in the blood. CancerSpot’s signatures, derived from Indian cohorts, have been shown to be robust and applicable across global ethnicities. The test provides a simple and convenient option for proactive and routine cancer screening. Isha Ambani Piramal, Member of the Board, Reliance Industries Limited, said, "Reliance is committed to pioneering breakthroughs that reshape the future of medicine in service of humanity. Cancer in India is emerging as a major cause of morbidity and mortality. It is a source of heavy financial, social and psychological burden on patients, families and communities. Therefore, Strand’s novel cancer early detection test exemplifies our vision of delivering transformative healthcare solutions. We are committed to utilising the power of genomics in advancing healthcare and wellness, and improving lives in India, as well as the rest of the world. Reliance translates its ‘WE CARE’ corporate philosophy into practice through each of our initiatives. The new Genomics Diagnostics & Research Centre demonstrates this yet again.” Speaking at the grand opening of Strand’s new state-of-the-art Genomics Diagnostics & Research Centre in Bengaluru, Dr. Ramesh Hariharan, CEO and Co-Founder, Strand Life Sciences, said, “Early warning is the key to battle cancer ─ and win it. We are proud to launch an accessible early cancer detection test that will enable people to stay ahead of cancer. Over our 24-year history, Strand has been a pioneer in genomics, and this is another FIRST for India resulting from a rigorous multi-year research study.” He further added, “This new Genomics Diagnostics & Research Centre will drive the CancerSpot program and accelerate efforts to develop new solutions, support research efforts, and deliver novel life-saving diagnostics for both Indian and global populations.” The Genomics Diagnostics & Research Center was inaugurated today by Dr. Charles Cantor, a global expert in genomics and biophysical chemistry, and previously Professor at Columbia University, UC Berkeley, and Boston University, in the presence of other luminaries in the field of genomics. This 33,000 square feet facility comprises a cutting-edge genomics laboratory with the latest sequencing technologies and workflows designed to foster collaboration among bioinformatics experts, molecular biologists, and clinical teams. For more information about CancerSpot, please visit strandls.com/early-detection